Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report released on Tuesday. The brokerage set a “hold” rating on the stock.

Oncternal Therapeutics Price Performance

ONCT opened at $0.53 on Tuesday. Oncternal Therapeutics has a 52 week low of $0.53 and a 52 week high of $9.88. The business’s 50 day moving average is $0.53 and its two-hundred day moving average is $1.17. The firm has a market cap of $1.56 million, a price-to-earnings ratio of -0.05 and a beta of 1.18.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.